Form 4: Citius Oncology CFO Receives Stock Options

Citius Oncology's Chief Financial Officer, Jaime Bartushak, was granted 400,000 stock options at an exercise price of $1.07, vesting over three years.

Summary

• Jaime Bartushak, the Chief Financial Officer of Citius Oncology, was granted 400,000 stock options on December 12, 2024.
• These options have an exercise price of $1.07 per share.
• The options will vest in three equal installments, one-third each on the one-year, two-year, and three-year anniversaries of the grant date, contingent on continuous service to the company.
• The options expire on December 12, 2034.
• Additionally, the document mentions previously granted options with an exercise price of $2.15, vesting over three years from July 5, 2023.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation through stock options, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications or surprises.

Positives

• The grant of stock options to the CFO aligns their interests with the company's long-term performance.
• The vesting schedule encourages the CFO's continued service to the company.

Risks

• The value of the stock options is dependent on the future performance of Citius Oncology's stock price.
• If the CFO leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to attract and retain key talent.
• Vesting schedules of three years are also common, ensuring long-term commitment from executives.
• The specific exercise prices and number of options granted would need to be compared to similar companies to assess if they are in line with industry norms.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, CFO, Jaime Bartushak, Citius Oncology, vesting, equity compensation